Literature DB >> 11254099

Aspects of the transmission of protection against Mycoplasma hyopneumoniae from sow to offspring.

E Rautiainen1, P Wallgren.   

Abstract

The aims of this study were to describe the variation in concentration of antibodies to Mycoplasma hyopneumoniae in the serum and colostrum of sows, and to compare the amount of antibodies in colostrum with that obtained in the serum of the smallest piglets in a litter. In addition, the efficacy of the passive immunity in natural conditions was studied. The study was performed in a sow pool herd (600 sows) that was endemically infected with M. hyopneumoniae. Blood samples were collected from sows 19 days (n = 25) before and 3 days (n = 15) after farrowing, and a colostrum sample (n = 25) was collected on the day of farrowing. All samples were analysed for antibodies to M. hyopneumoniae with a monoclonal blocking enzyme-linked immunosorbent assay (ELISA). Twelve sows (48%) were high-responders with respect to antibody concentration in colostrum. The amount of blocking decreased in serum during the last weeks of pregnancy and 3 days post-farrowing it was only 53% of the level found in colostrum. At the age of 14 days, 30 of the smallest piglets were weaned. They were divided into three experimental groups, being the offspring of high-responding sows, low-responding sows, or a mix of high- and low-responding sows. The groups were transported to three separated isolation units and were followed until slaughter. At slaughter, lung lesions were not found. Nor could M. hyopneumoniae be demonstrated either by cultivation or by polymerase chain reaction. However, a significant increase in absorbance values, assessed by an indirect-ELISA, was demonstrated in groups established from low-responding sows. It was concluded that a high antibody level in colostrum appeared to protect piglets from M. hyopneumoniae.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11254099     DOI: 10.1046/j.1439-0450.2001.00421.x

Source DB:  PubMed          Journal:  J Vet Med B Infect Dis Vet Public Health        ISSN: 0931-1793


  7 in total

1.  In vitro expression of the 50-kDa and 30-kDa fragments of the P97 adhesin of Mycoplasma hyopneumoniae in Escherichia coli and their use for serodiagnosis.

Authors:  Eun Jin Jang; Tae Jung Kim
Journal:  Can J Vet Res       Date:  2007-10       Impact factor: 1.310

2.  Vaccination of piglets up to 1 week of age with a single-dose Mycoplasma hyopneumoniae vaccine induces protective immunity within 2 weeks against virulent challenge in the presence of maternally derived antibodies.

Authors:  Stephen Wilson; Leen Van Brussel; Gillian Saunders; Paul Runnels; Lucas Taylor; Dan Fredrickson; Jeremy Salt
Journal:  Clin Vaccine Immunol       Date:  2013-03-13

3.  Transfer of Mycoplasma hyopneumoniae-specific cell mediated immunity to neonatal piglets.

Authors:  Bert Devriendt; Dominiek Maes; Evelien Biebaut; Lisa Beuckelaere; Filip Boyen; Freddy Haesebrouck; Charles-Oliver Gomez-Duran
Journal:  Vet Res       Date:  2021-06-30       Impact factor: 3.683

4.  Regional eradication of Mycoplasma hyopneumoniae from pig herds and documentation of freedom of the disease.

Authors:  E Rautiainen; J Oravainen; J V Virolainen; V Tuovinen
Journal:  Acta Vet Scand       Date:  2001       Impact factor: 1.695

5.  Maternal immunity enhances Mycoplasma hyopneumoniae vaccination induced cell-mediated immune responses in piglets.

Authors:  Meggan Bandrick; Kara Theis; Thomas W Molitor
Journal:  BMC Vet Res       Date:  2014-06-05       Impact factor: 2.741

6.  The immune mechanism of Mycoplasma hyopneumoniae 168 vaccine strain through dendritic cells.

Authors:  Yumeng Shen; Weiwei Hu; Yanna Wei; Zhixin Feng; Qian Yang
Journal:  BMC Vet Res       Date:  2017-09-15       Impact factor: 2.741

7.  Individual risk factors for Mycoplasma hyopneumoniae infections in suckling pigs at the age of weaning.

Authors:  Heiko Nathues; Stefanie Doehring; Henrike Woeste; Anna S Fahrion; Marcus G Doherr; Elisabeth grosse Beilage
Journal:  Acta Vet Scand       Date:  2013-06-03       Impact factor: 1.695

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.